… Q1 Revenue Dip ‘Temporary’, Says CFO The Mumbai-based pharmaceutical ingredients … end,” he told ETCFO. H2 to Outperform H1 with … Facility Supriya expects a stronger second half. According to Raghunathan, … will act rashly on pharma.” Global Strategy: Europe …

… to attack the pharmaceutical companies? Or hurt the revenues of the TV … :@?D 7@C H92E6G6C E96J H2?E]k^Am kAm%92E’D … EC2?DA=2?E DFC86@?[ H2?E65 E96 25D @77 E96 … ?5 H6 D9@F=5 H2?E =6256CD H9@ 2C6 23 …

… making a short-term profit. system. The BRICS+ … powerful nations and multinational pharmaceutical companies, declined to … free trade in the second half of the 19th century, … pharmaceutical companies, whose main motivation is the pursuit of maximum profits …

… DICJ), Macau's gaming revenue in the first half of … .77 billion. The gross revenue generated from VIP junkets during … of satellite casinos in the second half of the year has raised … declines, with the exception of pharmaceutical products and motor vehicles. …

… . All manufacturing is Cambridge-based, revenues have tripled and the company … . Shaun Grady, UK chairman of pharmaceutical giant AstraZeneca, introduced the major … released more products in the second half of last year than in …

… Control, Chemical Processing, Food Processing, Pharma Manufacturing and Processing. Cross-border … affluent enthusiast communities offers significant revenue potential. Taken together, these … August is any indication, the second half of 2025 has the strong …

… cut its 2025 full-year revenue forecast citing a “softening” … that purportedly occurred “in the second half of 2024.” On this news … cut its 2025 full-year revenue forecast. RxSight attributed the … as $420 million from Teva Pharmaceutical Ind. Ltd. For more …

… In Korea, where many drugmakers are still founder-led and … 76 percent of revenue last year. Total revenue in 2024 was … -resistant schizophrenia, with a second-half 2027 Korea launch possible if … pramipexole and rasagiline, from Pharma Two B; bioequivalence is …

… extensive experience across biotechnology, pharmaceuticals, healthcare technology, and … employee stock options. Revenue Total revenue was $10.7 … Pharmaceutical, partially offset by a decrease in license royalty revenues … be made in the second half of 2025. Net …

Oxford BioMedica PLC (LSE:OXB) has had a busy summer. The gene therapy manufacturer, now positioned as a contract development and manufacturing organisation (CDMO), raised £60 million in August and secured a new loan facility. According to Panmure Liberum, …